Briana L McGovern
Overview
Explore the profile of Briana L McGovern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiang Y, Xu J, McGovern B, Ranzenigo A, Huang W, Sang Z, et al.
Cell
. 2024 Oct;
187(24):6966-6980.e23.
PMID: 39447570
Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness...
2.
Lee A, Amick I, Aschenbrenner J, Barr H, Benjamin J, Brandis A, et al.
bioRxiv
. 2024 Sep;
PMID: 39229055
A strategy for pandemic preparedness is the development of antivirals against a wide set of viral targets with complementary mechanisms of action. SARS-CoV-2 nsp3-mac1 is a viral macrodomain with ADP-ribosylhydrolase...
3.
Rosales R, McGovern B, Rodriguez M, Leiva-Rebollo R, Diaz-Tapia R, Benjamin J, et al.
Antiviral Res
. 2024 Jul;
230:105970.
PMID: 39067667
Variants of SARS-CoV-2 pose significant challenges in public health due to their increased transmissibility and ability to evade natural immunity, vaccine protection, and monoclonal antibody therapeutics. The emergence of the...
4.
Boby M, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson M, et al.
Science
. 2023 Nov;
382(6671):eabo7201.
PMID: 37943932
We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. We discovered...
5.
Bouhaddou M, Reuschl A, Polacco B, Thorne L, Ummadi M, Ye C, et al.
Cell
. 2023 Sep;
186(21):4597-4614.e26.
PMID: 37738970
SARS-CoV-2 variants of concern (VOCs) emerged during the COVID-19 pandemic. Here, we used unbiased systems approaches to study the host-selective forces driving VOC evolution. We discovered that VOCs evolved convergent...
6.
Wei J, Patil A, Collings C, Alfajaro M, Liang Y, Cai W, et al.
Nat Genet
. 2023 Mar;
55(3):471-483.
PMID: 36894709
Identification of host determinants of coronavirus infection informs mechanisms of viral pathogenesis and can provide new drug targets. Here we demonstrate that mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) chromatin remodeling complexes, specifically...
7.
Thorne L, Bouhaddou M, Reuschl A, Zuliani-Alvarez L, Polacco B, Pelin A, et al.
Nature
. 2022 Mar;
604(7905):E14.
PMID: 35332335
No abstract available.
8.
Varona J, Landete P, Lopez-Martin J, Estrada V, Paredes R, Guisado-Vasco P, et al.
Life Sci Alliance
. 2022 Jan;
5(4).
PMID: 35012962
Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over...
9.
Thorne L, Bouhaddou M, Reuschl A, Zuliani-Alvarez L, Polacco B, Pelin A, et al.
Nature
. 2021 Dec;
602(7897):487-495.
PMID: 34942634
The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission. Although much effort has focused on the characterization of changes in the spike protein in variants...
10.
Tummino T, Rezelj V, Fischer B, Fischer A, OMeara M, Monel B, et al.
Science
. 2021 Jul;
373(6554):541-547.
PMID: 34326236
Repurposing drugs as treatments for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning with sigma receptor ligands and expanding to other...